DexCom Inc. (NASDAQ:DXCM) EVP Andrew K. Balo sold 5,000 shares of the business’s stock in a transaction dated Wednesday, October 5th. The stock was sold at an average price of $82.55, for a total transaction of $412,750.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Andrew K. Balo also recently made the following trade(s):
- On Wednesday, September 21st, Andrew K. Balo sold 5,000 shares of DexCom stock. The stock was sold at an average price of $92.87, for a total transaction of $464,350.00.
Shares of DexCom Inc. (NASDAQ:DXCM) opened at 82.93 on Friday. The firm’s market cap is $6.96 billion. DexCom Inc. has a 52-week low of $47.92 and a 52-week high of $96.38. The company’s 50-day moving average is $90.88 and its 200-day moving average is $77.91.
DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Tuesday, August 2nd. The medical device company reported ($0.24) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.12) by $0.12. DexCom had a negative net margin of 16.42% and a negative return on equity of 19.68%. The company earned $137.30 million during the quarter, compared to analyst estimates of $132.48 million. During the same quarter last year, the business earned ($0.05) EPS. The company’s revenue for the quarter was up 47.3% compared to the same quarter last year. Equities research analysts forecast that DexCom Inc. will post ($0.57) earnings per share for the current fiscal year.
Several institutional investors have recently added to or reduced their stakes in DXCM. Bridger Management LLC bought a new position in DexCom during the first quarter worth $56,651,000. State Street Corp raised its position in DexCom by 7.2% in the first quarter. State Street Corp now owns 1,055,774 shares of the medical device company’s stock worth $71,699,000 after buying an additional 71,009 shares during the period. Renaissance Technologies LLC raised its position in DexCom by 17.9% in the first quarter. Renaissance Technologies LLC now owns 817,943 shares of the medical device company’s stock worth $55,547,000 after buying an additional 124,000 shares during the period. Calamos Advisors LLC bought a new position in DexCom during the second quarter worth $22,764,000. Finally, American Century Companies Inc. raised its position in DexCom by 7.3% in the second quarter. American Century Companies Inc. now owns 806,639 shares of the medical device company’s stock worth $63,991,000 after buying an additional 54,684 shares during the period. Institutional investors and hedge funds own 99.37% of the company’s stock.
DXCM has been the topic of several recent research reports. Zacks Investment Research lowered shares of DexCom from a “hold” rating to a “strong sell” rating in a research report on Tuesday. BMO Capital Markets assumed coverage on shares of DexCom in a report on Friday, September 16th. They issued an “outperform” rating and a $112.00 target price on the stock. Desjardins upgraded shares of DexCom from a “hold” rating to a “buy” rating in a report on Friday, September 16th. Leerink Swann restated an “outperform” rating and issued a $90.00 target price on shares of DexCom in a report on Wednesday, July 20th. Finally, BTIG Research lowered shares of DexCom from a “buy” rating to a “neutral” rating and set a $92.00 target price on the stock. in a report on Wednesday, September 14th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $95.08.
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.